Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant short-course radiotherapy followed by sintilimab, anlotinib, and XELOX for MSS/pMMR locally advanced rectal cancer
ChiCTR2100054135Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of sintilimab, anlotinib, capecitabine and oxaliplatin, sponsored by The First Affiliated Hospital of Zhengzhou University. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
sintilimabanlotinibcapecitabineoxaliplatin
Beyond the preview
Go deeper on ChiCTR2100054135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054135.